CFN Media

April 04, 2017 09:00 ET

Emerald Health Included in Upcoming Cannabis ETF -- CFN Media

SEATTLE, WA--(Marketwired - Apr 4, 2017) -  CFN Media Group ("CFN Media"), the leading agency and digital media network dedicated to legal cannabis, today announced publication of an article covering the inclusion of Emerald Health Therapeutics Inc. (TSX VENTURE: EMH) in Horizons ETFs Management (Canada) Inc.'s new ETF focused on the cannabis industry.

Exchange-traded funds (ETFs) have become extremely popular over the past decade as investors seek out easier ways to build and maintain a portfolio. At the same time, the cannabis industry has grown into a multi-billion dollar opportunity with an increasing number of public companies in the space. It's only natural that a pure-play ETF would eventually come along and make it easier for investors to buy into the lucrative space.

On March 28, Horizons ETFs Management (Canada) Inc. announced that it filed its final prospectus to launch the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The new ETF, set to begin trading on April 5, will become the first publicly-traded fund offering direct exposure to North American-listed stocks that are involved with medical marijuana bioengineering and production -- a booming market in recent years.

The underlying North American Medical Marijuana Index is designed to be a liquid and investable index of equity securities of publicly-traded companies involved in the cannabis industry. Only stocks that meet minimum asset and liquidity thresholds are considered for inclusion in the index, which is rebalanced quarterly on a market capitalization basis and capped so that no single stock can exceed 10% of the weight of the index when rebalanced.

Emerald Health Therapeutics Inc. is the seventh largest holding in the index with a roughly 6.6% allocation, as of April 3, 2017, which means that it would receive that percentage of any new investment capital. Emerald Health is a Canadian Licensed Producer whose world-class management team and Board of Directors have carried out a combined $1+ billion in clinical trials and raise over $500 million in funding. The company secured federal funding to characterize cannabis strains from the Canadian National Research Counsel's Industrial Research Assistance Program ("NRC-IRAP") in 2015, and has since developed a product line with a high level of genetic and product diversity. Emerald also intends to conduct clinical trials of its own to demonstrate the utility of its broad product lines.

Please follow the link to read the full article:

Learn how to become a CFN Media featured company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information